Journal of Medicinal Chemistry

D P f Goodford 1985. A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules. Journal of Medicinal Chemistry 28 849-857. Molecular Discovery Ltd, Oxford, United Kingdom. 

Eriksson M A L, J Pitera and P A Kollman 1999. Prediction of the Binding Free Energies of New TIBO-like HIV-1 Reverse Transcriptase Inhibitors Using a Combination of PROFEC, PB/SA, CMC/MD, and Free Energy Calculations. Journal of Medicinal Chemistry 42 868-881. 

W P Walters and M A Murcko 1998. Can We Learn to Distinguish Between Drug-like and indrug-like Molecules Journal of Medicinal Chemistry 41 3314-3324. 

T A and H Kalayeh 1991. Applications of Neural Networks in Quantitative Structure-Activity ationships of Dihydrofolate Reductase Inhibitors, journal of Medicinal Chemistry 34 2824-2836. ik M and R C Glen 1992. Applications of Rule-induction in the Derivation of Quantitative icture-Activity Relationships. Journal of Computer-Aided Molecular Design 6 349-383. 

Charifson P S, J J Corkery, M A Murcko and W P Walters 1999. Consensus Scoring A Method fc Obtaining Improved Hit Rates from Docking Databases of Three-Dimensional Structures int Proteins. Journal of Medicinal Chemistry 42 5100-5109. 

Desjarlais R L, R P Sheridan, G L Seibel, J S Dixon, ID Kuntz and R Venkataraghavan 1988. Using Shap Complementarity as an Initial Screen in Designing Ligands for a Receptor Binding Site of Know Three-Dimensional Structure. Journal of Medicinal Chemistry 31 722-729. 

J S, I Morize, P R Menard, D L Cheney, C Hulme and R F Labaudiniere 1999. New 4-Point irmacophore Method for Molecular Similarity and Diversity Applications Overview of the thod and Applications, Including a Novel Approach to the Design of Combinatorial iraries Containing Privileged Substructures. Journal of Medicinal Chemistry 42 3251-3264. 

Pastor M, G Cruciani and S dementi 1997. Smart Region Definition A New Way to Improve tl Predictive Ability and Interpretability of Three-Dimensional Quantitative Structure-Activi Relationships. Journal of Medicinal Chemistry 40 1455-1464. 

Sadowski J and H Kubinyi 1998. A Scoring Scheme for Discriminating Between Drugs and Nondrug Journal of Medicinal Chemistry 41 3325-3329. 

Sheridan R P, R Ndakantan, J S Dixon and R Venkataraghavan 1986. The Ensemble Approach to Distanc Geometry Application to the Nicotinic Pharmacophore. Journal of Medicinal Chemistry 29 899-906. 

Harmon RE., Dabrowiak JC., Brown DJ., Gupta SK., Herbert M., and Chitharanjan D. Metal Complexes of 1-Substituted 3-Hydroxyureas. Journal of Medicinal Chemistry, 1970, 13(3), 577-579. 

Beaulieu, R L., Wernic, D., Abraham, A., et al., 1997. Potent HIV protea.se inhibitors containing a novel (hydroxyethyl)amide i.so.stere. Journal of Medicinal Chemistry 40 2164—2176. 

Moustatih, A., and Garnier-Suillerot, A. (1989) Bifunctional antitumor compounds synthesis and characterization of a gold(III)-streptonigrin complex with thiol-modulating properties. Journal of Medicinal Chemistry, 32, 1426. 

Navarro, M., Vasquez, F., Sanchez-Delgado, R.A., Perez, H., Sinou, V. and Schrevel, J. (2004) Toward a Novel Metal-Based Chemotherapy against Tropical Diseases. 7. Synthesis and in Vitro Antimalarial Activity of New Gold-Chloroquine Complexes. Journal of Medicinal Chemistry, 47, 5204. 

Messori, L, Abbate, F., Marcon, G., Orioli, P., Fontani, M., Mini, E., Mazzei, T., Carotti, S., O Connell, T. and Zanello, P. (2000) Gold(lll) complexes as potential antitumor agents solution chemistry and cytotoxic properties of some selected gold(III) compounds. Journal of Medicinal Chemistry, 43, 3541. 

Casini, A., Cinellu, M.A., Minghetti, G., Gabbiani, C., Coronnello, M., Mini, E. and Messori, L. (2006) Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinudear gold(l II) compounds with bipyridyl ligands. Journal of Medicinal Chemistry, 49, 5524. 

Sutton, B.M., McGusty, E., Walz, D.T. and DiMartino, M.J. (1972) Antiarthritic properties of alkylphosphinegold coordination complexes. Journal of Medicinal Chemistry, 15, 1095-1098. 

Berners-Price, S., Girard, G.R. and Hill, D.T. (1990) Cytotoxicity and antitumor activity of some tetrahedral bis(diphosphino)gold(l) chelates. Journal of Medicinal Chemistry, 33, 1386-1392. 

Veith, M., Siegel, M.G., Higgs, R.E. et al. (2004) Characteristic Physical Properties and Structural Fragments of Marketed Oral Drugs. Journal of Medicinal Chemistry, 47, 224-232. 

Veber, D.F., Johnson, S.R., Cheng, H.Y., Smith, B.R., Ward, K.W., Kopple, K.D. (2002) Molecular Properties that Influence the Oral BioavaUability of Drug Candidates. Journal of Medicinal Chemistry, 45, 2671-2623. 

Ajay Walters, W.P., Murcko, M.A. (1998) Can we Learn to Distinguish between Drug-like and Non-Drug-like Molecules Journal of Medicinal Chemistry, 41, 3314—3224. 

Wenlock, M.C., Austin, R.P., Barton, P., Davis, A.M., Leeson, P.D. (2003) A Comparison of Physicochemical Property Profiles of Development and Marketed Oral Drugs. Journal of Medicinal Chemistry, 46,1250-1256. 

Rice, K.C. (1977) A Rapid, High-Yield Conversion ofCodeineto Morphine. Journal of Medicinal Chemistry, 20, 164-165. 

Weller, D.D. 8c Rapoport, H. (1976) A Practical Synthesis of Codeine from Dihydrothebainone. Journal of Medicinal Chemistry, 19, 1171-1175. 

Hsin, L.-W., Dersch, C.M., Baumann, M.H. et al. (2002) Development of long-acting dopamine transporter ligands as potential cocaine-abuse therapeutic agents chiral hydroxyl-containing derivatives of l-[2-[bis (4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and l-[2-(diphenylmethoxy)ethyl]-4-(3-phe-nylpropyl)piperazine. Journal of Medicinal Chemistry, 45 (6), 1321-1329. 

Tagat, J.R., Steensma, R.W., McCombie, S.W. et al. (2001) Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1 - [(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4- [3 (S)-methyl-4- [ 1 (5)- [4-(trifluoro- methyl)phenyl]ethyl]-l-piperazinyl]-piperidine Nl-oxide (sch-350634), an orally bioavailable, potent CCR5 antagonist. Journal of Medicinal Chemistry, 44 (21), 3343-3346. 

Aicher, T.D., Anderson, R.C., Bebernitz, G.R.,ei al. (1999) (/ )-3,3,3-Trifluoro-2-hydroxy-2-methylpropiona-mides are orally active inhibitors of pyruvate dehydrogenase kinase. Journal of Medicinal Chemistry, 42, 2741-2746. 

Hutchinson, C.R., Borell, C.W., Otten, S.L. et al. (1989) A perspective on drug discovery and development through the genetic engineering of antibiotic-producing microorganisms. Journal of Medicinal Chemistry, 32, 929. 

Stromgaard K, Saito DR, Shindou H, Ishii S, Shimizu T and Nakanishi K (2002). Ginkgolide derivatives for photolabeling studies Preparation and pharmacological evaluation. Journal of Medicinal Chemistry, 45, 4038-4046. 

Bennett, M.J., Aberle A.M., Balasubramaniam R.P., Malone, J.G., Malone, R.W., and Nantz, M.H., Cationic lipid-mediated gene delivery to murine lung correlation of lipid hydration with in vivo transfection activity, Journal of Medicinal Chemistry, 1997, 40, 4069 1078. 

Cooper, G.H., I.W. Lawston, R.L. Rickard, and T.D. Inch. "Structure-Activity Relations in 2,6,7-Trio xa-l-phosphabicyclo[2.2.2]octanes and Related Compounds." European Journal of Medicinal Chemistry 13 (1978) 207-212. 

This kind of study can be of great interest in medicinal chemistry (as is also apparent from the publication of the results from one such study in the Journal of Medicinal Chemistry), because it can be used predict the behavior of the radiopharmaceutical on injection in the human body. These investigations can also be of relevance in the rational design of new radiopharmaceuticals performed with a view to designing more stable and less toxic compounds. 

JHC = Journal of Heterocyclic Chemistry JMC = Journal of Medicinal Chemistry JOC = Journal of Organic Chemistry JPS = Journal of Pharmaceutical Science LAC = Leibigs Annalen der Chemie MON = Monatshefte fur Chemie REC = Recueil Travaux Chemiques TET = Tetrahedron TL = Tetrahedron Letters... 

---